Correlation Engine 2.0
Clear Search sequence regions

  • and virus (1)
  • antigens cd34 (3)
  • blood banks (3)
  • CD34 (5)
  • cord blood (3)
  • donor (3)
  • fetal blood (1)
  • fraction cell (1)
  • GMP (1)
  • HLA (4)
  • microbeads (1)
  • research (1)
  • stem cell (7)
  • Sizes of these terms reflect their relevance to your search.

    The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy. © 2022. The Author(s).


    Belén Álvarez-Palomo, Anna Veiga, Angel Raya, Margarita Codinach, Silvia Torrents, Laura Ponce Verdugo, Clara Rodriguez-Aierbe, Leopoldo Cuellar, Raquel Alenda, Cristina Arbona, Dolores Hernández-Maraver, Cristina Fusté, Sergi Querol. Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells. Stem cell research & therapy. 2022 Aug 12;13(1):408

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35962457

    View Full Text